PRU Shares Perseus Mining Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Oncology asset development offers binary upside if clinical and regulatory milestones progress successfully.
Future value: $6.77 (+21.13%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Speculative oncology pipeline provides milestone-driven optionality.
- ▾Below 50-day MA (-11.83%)
- ▸~21% upside to price target
Is PRU a buy right now?
Trend: PRU is trading below the 50-day average (-11.83%), RSI 51 — neutral momentum, with a 3-month return of +15.02%.
Valuation & quality: Perseus Mining Limited trades on a trailing P/E of 11.6, forward P/E 7.1, PEG 1.61, price-to-book 2.27; fundamentals show net margin 28.9%, return on equity 20.6%, revenue growth 31.4% year on year.
Analyst consensus: 7 analysts have a mean 12-month price target of A$6.77 (+21.1% vs the last close; range A$3.20 – A$8.95), consensus rating “buy”.
Income: trailing dividend yield 2.59%.
Our screen: ACCUMULATE (score 1) — Oncology asset development offers binary upside if clinical and regulatory milestones progress successfully.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.50% | +0.00% | -4.80% | -7.20% | +1.00% | +33.60% | -0.20% | -13.60% |
Fundamentals
Analyst price target
Technical signals
About Perseus Mining Limited
Perseus Mining Limited, together with its subsidiaries, explores, evaluates, develops, and mines for gold properties in Ghana, Côte d'Ivoire, Tanzania, and Sudan.
Sector: Basic Materials · Industry: Gold · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.